Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.47 |
| ▸ | GBA1 | P04062 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | RAF1 | P04049 | 2/20 | 0.45 |
| ▸ | BRAF | P15056 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HTR1B | P28222 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1271286 | 0.89 | RAF1 (0.53) | MAPTKDM4EHIF1AGBA1ALDH1A1 | |
| SCHEMBL11926300 | 0.84 | GRM4 (0.47) | MAPTKDM4EHIF1AGBA1ALDH1A1 | |
| SCHEMBL1271164 | 0.81 | GBA1 (0.47) | MAPTKDM4EHIF1AGBA1ALDH1A1 | |
| SCHEMBL11926330 | 0.78 | MAPT (0.46) | MAPTKDM4EHIF1AGBA1ALDH1A1 | |
| SCHEMBL427421 | 0.77 | GRM4 (0.47) | MAPTKDM4EALDH1A1SMN1; SMN2RAF1 | |
| SCHEMBL11926320 | 0.76 | GBA1 (0.45) | MAPTKDM4EHIF1AGBA1ALDH1A1 | |
| SCHEMBL11926318 | 0.76 | NPC1 (0.44) | MAPTKDM4EHIF1AGBA1ALDH1A1 | |
| SCHEMBL11926373 | 0.76 | RAF1 (0.40) | MAPTKDM4EALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL13439960 | 0.75 | RAF1 (0.44) | MAPTKDM4EHIF1AGBA1ALDH1A1 | |
| SCHEMBL11926402 | 0.74 | MAPT (0.44) | MAPTKDM4EGBA1ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034454-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2011-02-10 | — | — | US | claimed |
| EP-1979325-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2008-10-15 | — | — | EP | claimed |
| WO-2007080382-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2007-07-19 | — | — | WO | claimed |
| US-8236795-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236795-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20110034454-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2011-02-10 | — | — | US | disclosed |
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-10-07 | — | — | US | disclosed |
| US-7696202-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-13 | — | — | US | disclosed |
| EP-1979325-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007080382-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034454-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY | TYMP, TYMS, PIK3CA | MAPT 2984/4885KDM4E 1201/4885HIF1A 1443/4885 |
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | IL2, IL4, IFNG | MAPT 3259/4885KDM4E 3666/4885HIF1A 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.